WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo

WAKAMOTO PHARMACEUTICAL CO.,LTD.

Develops and sells pharmaceuticals, medical devices, and health foods.

4512 | T

Overview

Corporate Details

ISIN(s):
JP3991200001
LEI:
Country:
Japan
Address:
中央区日本橋本町二丁目2番2号

Description

WAKAMOTO PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, production, and sale of pharmaceuticals. Its business encompasses both ethical (prescription) drugs and over-the-counter (OTC) products, as well as medical devices and health foods. The company specializes in therapeutic areas such as gastroenterology and is known as a pioneer in self-medication, with its flagship product being the nutrient-rich gastrointestinal remedy, "WAKAMOTO". The company actively manages a drug pipeline and engages in clinical trials to bring new therapeutic solutions to market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2022-06-24 04:06
有価証券報告書-第127期(令和3年4月1日-令和4年3月31日)
Japanese ZIP 719.0 KB
2022-02-14 01:07
四半期報告書-第127期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese ZIP 158.8 KB
2021-11-12 02:14
四半期報告書-第127期第2四半期(令和3年7月1日-令和3年9月30日)
Japanese ZIP 186.2 KB
2021-08-06 02:09
四半期報告書-第127期第1四半期(令和3年4月1日-令和3年6月30日)
Japanese ZIP 155.5 KB
2021-06-25 02:20
内部統制報告書-第126期(令和2年4月1日-令和3年3月31日)
Japanese ZIP 21.8 KB
2021-06-25 02:19
確認書
Japanese ZIP 8.1 KB
2021-06-25 02:18
有価証券報告書-第126期(令和2年4月1日-令和3年3月31日)
Japanese ZIP 709.6 KB
2021-02-12 01:08
四半期報告書-第126期第3四半期(令和2年10月1日-令和2年12月31日)
Japanese ZIP 146.5 KB
2020-11-13 01:10
四半期報告書-第126期第2四半期(令和2年7月1日-令和2年9月30日)
Japanese ZIP 175.9 KB
2020-08-07 02:10
四半期報告書-第126期第1四半期(令和2年4月1日-令和2年6月30日)
Japanese ZIP 142.8 KB
2020-06-25 02:11
有価証券報告書-第125期(平成31年4月1日-令和2年3月31日)
Japanese ZIP 690.3 KB
2020-02-13 01:08
四半期報告書-第125期第3四半期(令和1年10月1日-令和1年12月31日)
Japanese ZIP 143.8 KB
2019-11-13 01:08
四半期報告書-第125期第2四半期(2019/07/01-2019/09/30)
Japanese ZIP 173.7 KB
2019-08-09 02:09
四半期報告書-第125期第1四半期(2019/04/01-2019/06/30)
Japanese ZIP 143.1 KB
2019-06-24 02:50
有価証券報告書-第124期(平成30年4月1日-平成31年3月31日)
Japanese ZIP 681.3 KB

Automate Your Workflow. Get a real-time feed of all WAKAMOTO PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for WAKAMOTO PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for WAKAMOTO PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.